ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Differential expression of NEAT1 and miR-506-3p in triple-negative breast cancer: potential tissue-based diagnostic biomarkers.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, and is one of the most challenging cancers to treat. Non-coding RNAs have been identified as potential biomarkers for various diseases, including cancer. Identifying these biomarkers may facilitate early diagnosis and improve treatment strategies. Therefore, this study aimed to evaluate the non-coding RNAs NEAT1 and miR-506-3p expression levels in TNBC patients.
methodsFormalin-fixed, paraffin-embedded (FFPE) tumor tissues and paired adjacent non-tumor tissues were obtained from 35 TNBC patients. Total RNA was extracted, and the expression levels of NEAT1 and miR-506-3p were quantified by qPCR using GAPDH and U6 as internal controls, respectively. Relative expression was analyzed by the 2
resultsNEAT1 was significantly upregulated (≈eightfold, P < 0.0001) and miR-506-3p was markedly downregulated (≈fivefold, P < 0.0001) in tumor tissues compared to adjacent non-tumor samples. Elevated NEAT1 expression was significantly associated with the younger age group, necrosis, calcification status, larger tumor size, and vascular invasion, whereas no significant associations were observed with BMI, tumor grade, or lymph-node involvement (P > 0.05). MiR-506-3p expression showed no significant clinicopathological differences in subgroup analysis. A significant inverse correlation was observed between NEAT1 and miR-506-3p levels (rs = -0.33, P < 0.05). ROC curve analysis showed promising discriminatory performance for NEAT1 in the present cohort (AUC = 0.9563, 95% CI 0.9165-0.9961; estimated sensitivity = 1.00, specificity = 0.77) and moderate discriminatory performance for miR-506-3p (AUC = 0.7971, 95% CI 0.6946-0.8997). A logistic regression model combining both markers showed improved discrimination in this dataset (AUC = 0.9739).
conclusionOur findings suggest that NEAT1 and miR-506-3p exhibit opposite expression patterns in TNBC tissues and may serve as complementary tissue-based candidate diagnostic biomarkers. Their combined use showed improved discriminatory performance in this cohort; however, larger independent validation studies are required before a clinical diagnostic application can be proposed.
Indexed as
Identifiers
42295648What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.